Answers are grounded in this paper and cite their sources.
Focused use of dendritic cell (DC) vaccination strategies is under investigation to address the therapeutic gap that persists for difficult-to-treat malignancies. In vulnerable pediatric populations, DC immunotherapy can be added to standard-of-care treatments to strengthen anti-tumor immunity without increasing toxicity. Based on this rationale, our center initiated the ADDICT-pedGLIO clinical trial, investigating Wilms' tumor protein (WT1)-directed DC vaccination as supplementary treatment for pediatric diffuse midline gliomas and high-grade gliomas. Although monocyte apheresis and subsequent DC vaccine manufacturing have been reported to be feasible in pediatric populations, publicly available data describing the practical aspects of pediatric CD14+ monocyte apheresis and their implications for subsequent DC production remain limited. This limits the evidence base available to inform standardized, risk-stratified approaches to pediatric monocyte collection. Data were collected from 10 children with pediatric high-grade glioma or diffuse midline glioma in the ADDICT-pedGLIO trial and 22 adults who underwent apheresis and WT1 mRNA-electroporated DC vaccine production. Patient characteristics, apheresis parameters, yields, and DC phenotypes were compared between cohorts and correlated with CD14+ monocyte yield, DC viability, and adverse events. Blood volume, flow rate, processed blood volume, and baseline monocyte count correlated positively with CD14+ yield and collection efficiency, while repeated blood volume processing increased adverse events and reduced efficiency. When these findings are considered during pediatric CD14+ monocyte apheresis planning, larger total blood volumes may be processed to maximize yield and the number of therapeutic vaccines. We recommend a minimum peripheral monocyte count of 240/μL before apheresis, routine use of central venous catheters, and close electrolyte monitoring in children. Translating adult experience to the pediatric setting, this prospective monocentric clinical trial provides a reference framework for safe, successful monocyte apheresis and subsequent therapeutic DC vaccine production. Trial Registration: ClinicalTrials.gov identifier: NCT04911621.
No takes yet. Share an insight, caveat, or question.
Genechten et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: